LYRA Stock: Lyra Therapeutics, Inc. Stock Price, Analysis & Insights
Get live lyra stock price $3.65, comprehensive Lyra Therapeutics, Inc. stock analysis, charts, news, and expert forecast. Real-time lyra stock data and investment insights.
Loading chart...
Company Overview
Lyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of anti-inflammatory therapies for the treatment of patients with chronic rhinosinusitis. Its technology is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix which is in Phase III clinical trial for the treatment of chronic rhinosinusitis (CRS); and LYR-220 for CRS patients who have failed previous medical management and continue to require treatment to manage CRS symptoms. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.
Company Information
- CEO
- Maria Palasis
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 30
Contact Information
- Website
- https://lyratherapeutics.com
- Address
- 480 Arsenal Way
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: -0.04) may provide portfolio stability
Business Model & Strategy
Lyra Therapeutics, Inc. operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Maria Palasis, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Lyra Therapeutics, Inc. competes in the Biotechnology within the broader Healthcare. With 6.5 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Lyra Therapeutics, Inc. provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Lyra Therapeutics, Inc. should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Lyra Therapeutics, Inc. shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Lyra Therapeutics, Inc.
- ⚠Investors should consider how Lyra Therapeutics, Inc. fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
6.48M
P/E Ratio
-0.16
Beta
-0.04
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 6.48M market capitalization
- Trading Volume: 49.55K shares traded today
- Price Range: 52-week range of $2.84 - $37.50
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc. (LYRA) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 6.48M, the company represents a significant player in its market. The stock is currently trading at $3.65 with a positivedaily change of 26.67%.
The company's 30 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.16, beta of -0.04, and 52-week price range from $2.84 to $37.50when evaluating investment opportunities.
Why Invest in Lyra Therapeutics, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Maria Palasis
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.